Did someone bet in advance again? $UTHR
A significant announcement comes today from United Therapeutics Corporation, which reported impressive success in a key clinical study named TETON-1 – this is a trial examining the efficacy of the drug Tyvaso for treating a complex disease called idiopathic pulmonary fibrosis.
To understand the significance, it is important to know the professional terms:
Idiopathic pulmonary fibrosis: This is a chronic disease in which lung tissue becomes thick and scarred, making it very difficult for oxygen to pass into the bloodstream and creating increasing breathing difficulties – the term "idiopathic" simply means that the cause of the disease is currently unknown to medicine.
Primary endpoint: This is the most important goal researchers set in advance to prove the drug works.
In this case – the fact that the study met the endpoint means that the drug significantly improved or preserved lung function in patients.
The data emerging from the field are very encouraging – as the results of the TETON-1 study were even better than the impressive results observed in the company's previous study. (TETON-2)
Furthermore – this success strengthens Tyvaso's position as a leading potential solution for patients suffering from severe breathing difficulties.
But what particularly interests us is the invisible hand that bet on this big move in advance!
Two weeks ago – on 03/11/2026, two very rare options trades were made on $UTHR stock.
The total premium amount exceeds $4,000,000.
The expiration date is in a little over two weeks,
The strike price is $600-$610.
What is particularly interesting is that on the options purchase date, $UTHR stock price was near an all-time high – around $545 per share.
We ask you,
Is it logical for someone to buy call options for $4 million at an all-time high?
Today – the company is updating the news we mentioned above.
The stock price is currently up about 17% in pre-market trading and is exceeding $600 per share!
We will continue to monitor and update.